Novartis AG operates in the Pharmaceutical preparations sector.
In addition to historical fundamental analyses, the complete report available to purchase compares Novartis with three other
pharmaceutical manufacturers in Europe:
sales of 34.71 billion Euro [US$40.74 billion]
of which 84%
(46.77 billion Euro [US$54.89 billion]
of which 35%
was Pharmaceuticals & Biological Products), and
Roche Holding Aktiengesellschaft
(50.58 billion Swiss Francs [US$51.98 billion]
of which 77%
Novartis reported sales of 48.83 billion Swiss Francs (US$50.18 billion)
December of 2016.
a very small
increase of 0.6%
versus 2015, when the company's sales were 48.55 billion Swiss Francs.
Despite this increase, sales are still
below the level achieved in 2014, when Novartis
reported sales of 48.98 billion Swiss Francs.
The sales level in 2016 was fairly close to the level five years ago: in 2011, Novartis had sales
of 51.57 billion Swiss Francs.
Sales of Sandoz saw an increase
that was more than double the company's growth rate: sales were up
13.6% in 2016, from
8.83 billion Swiss Francs to 10.03 billion Swiss Francs.
Novartis also saw significant increases in sales in
Innovative Medicines (up 9.7% to 32.19 billion Swiss Francs)
Not all segments of Novartis experienced an increase in sales in 2016:
sales of Alcon fell 39.3% to 5.75 billion Swiss Francs.